Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase 1 and Randomized Phase 2 Trial of Selinexor and Temozolomide in Recurrent Glioblastoma

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT05432804
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-25T22:27:56.863941+00:00
Published At
2026-04-13T00:00:00+00:00
Record Updated At
2026-04-13
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["MGMT-Methylated Glioblastoma", "Recurrent Glioblastoma, IDH-Wildtype", "Recurrent MGMT-Methylated Glioblastoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2026-04-13"
protocolSection.identificationModule.nctId
"NCT05432804"
protocolSection.identificationModule.officialTitle
"A Phase 1 and Randomized Phase 2 Trial of Selinexor and Temozolomide in Recurrent Glioblastoma"
protocolSection.statusModule.overallStatus
"SUSPENDED"
protocolSection.designModule.phases
["PHASE1", "PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
""

Study condition terms

  • MGMT-Methylated Glioblastoma (protocolSection.conditionsModule.conditions)
  • Recurrent Glioblastoma, IDH-Wildtype (protocolSection.conditionsModule.conditions)
  • Recurrent MGMT-Methylated Glioblastoma (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.